GlassScriptPhysician profile
Elsa I Santellano
NPI 1952021545
$1,477.32
in general payments reported to CMS, 2019-2025
21 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $204 · 2023: $461 · 2024: $436 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $326.99 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $323.99 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $200.57 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.86 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $78.25 | 2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $68.08 | 2023-2025 | Verquvo, Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $46.95 | 2024 | Voquezna |
| Exact Sciences Corporation | $40.05 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $33.42 | 2023-2024 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $33.39 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $29.16 | 2024 | |
| Corcept Therapeutics | $22.36 | 2025 | Korlym |
| Lundbeck LLC | $22.17 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.84 | 2023 | Farxiga |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.49 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.32 | 2023 | Seglentis |
| Organon LLC | $14.17 | 2023 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.34 | 2024 | Xifaxan |
| Pfizer INC. | $13.25 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsa Santellano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.